chapter 30 of 52 · the reptides guide

Dutasteride

Dutasteride lowers DHT by blocking two forms of an enzyme. Its main clinical evidence concerns an enlarged prostate and male-pattern hair loss.

7 pages in the book · 25 sources cited · Dutasteride on the wiki

An enlarged prostate

Across three US-label trials involving 4,325 men, urinary retention occurred in 1.8% with dutasteride and 4.2% with placebo over two years. Prostate-related surgery occurred in 2.2% and 4.1%, respectively.840

Country-specific approvals

The US Avodart label covers BPH. Japan’s Zagallo label includes male-pattern hair loss.840,841

Formulations

Topical research

A 135-man phase 2 trial reported improved hair counts with one specific solution. It detected dutasteride in blood and has unresolved discrepancies in participant totals and exposure reporting.842

Regional studies

Chinese BPH studies include uncontrolled add-on treatment and retrospective predictors of retention or surgery. A small Iranian oral-hair trial found no significant difference from finasteride at 24 weeks.845,846,847

Sexual effects, fertility and mood

Fertility measurements

Studies report changes in sperm count, semen volume and motility. The newer 200-man clinic study lacked pre-treatment semen measurements and an untreated comparison group.840,848

Updated mood warnings

Regulators added precautionary warnings after reviewing the drug class. The European review found insufficient evidence for a direct dutasteride link; UK advice calls for medical contact if depression or suicidal thoughts occur.849,850

Slow clearance

The US label gives a steady-state half-life of about five weeks and detectability for four to six months after stopping. It also covers pregnancy exposure, PSA interpretation and persistent sexual effects.840

Common questions

01 Does dutasteride work better than finasteride for hair loss?

In the 917-man trial, posted results show adjusted gains of 89.6 hairs with dutasteride versus 56.5 with finasteride at 24 weeks, measured in a 2.54-cm-wide target circle. Dutasteride also performed better on hair width and frontal photographs. These figures describe the studied oral products and men aged 20 to 50.851,839

02 Did the lower-dose trial prove equal results?

The Korean trial included 139 men and treated its higher-dose group as exploratory. The study supports a hair-count benefit over placebo; it was not a formal equivalence trial.852

03 Why did the mood warnings change?

Regulators added precautionary mood warnings after reviewing this drug class. The European review found insufficient evidence for a direct link between dutasteride and suicidal thoughts; UK and Russian notices carry that distinction. The UK notice advises medical contact for depression or suicidal thoughts.849,850,853

04 What do the intermittent-treatment studies show?

A 60-man pilot compared two intermittent dutasteride schedules with daily finasteride. Hair growth improved in all groups. The more frequent dutasteride schedule did not significantly outperform finasteride on hair count over 24 weeks.854

05 Can dutasteride affect sperm?

Yes. The US label reports reductions in sperm count, semen volume and motility in healthy volunteers. Average values remained within normal ranges, while two men had sperm-count reductions greater than 90%. The studies leave individual fertility outcomes uncertain.840

06 What does the newer fertility study add?

A 2025 study followed 200 men attending a fertility clinic after using dutasteride. Some semen measures remained impaired six months after stopping. The study lacked pre-treatment semen results and an untreated group, which limits what it can establish about cause and recovery.848

07 Why does the label warn about leaking capsules?

Dutasteride can pass through skin. The pregnancy warning concerns possible harm to the development of a male fetus, so the label warns pregnant people against handling leaking capsules.840

08 Why is there a blood-donation waiting period?

The US label sets a six-month wait after the last dose to prevent a pregnant transfusion recipient from receiving dutasteride. The drug clears slowly.840

09 Does a lower PSA mean a lower cancer risk?

Dutasteride itself lowers PSA, often by about half within three to six months. Clinicians account for that effect when interpreting results. The label also warns about more high-grade cancers in a prostate-cancer prevention trial.840

10 Is dutasteride approved for hair loss anywhere?

Japan’s Zagallo label includes male-pattern hair loss. The US Avodart label covers an enlarged prostate. Approval depends on the country, product and indication.841,840

11 Does topical dutasteride stay entirely in the scalp?

The 2025 topical trial detected dutasteride in blood. It tested one specific solution and a small pharmacokinetic subgroup. Its exposure table and narrative report different peak values.842

12 How convincing is the topical trial?

It reports improved hair counts over 24 weeks, including a benefit over oral finasteride for the highest-strength solution. The study was small and manufacturer-funded. Participant totals and some safety and blood-level reporting need clarification.842

13 What benefit was shown for an enlarged prostate?

Across three US-label trials involving 4,325 men, dutasteride improved urinary symptoms over two years. Acute urinary retention occurred in 1.8% with dutasteride versus 4.2% with placebo; prostate-related surgery occurred in 2.2% versus 4.1%.840

14 Are there hair-loss studies longer than six months?

Yes. A year-long placebo-controlled trial enrolled 17 identical twin pairs; 16 completed it, with hair assessments favoring dutasteride. A separate Japanese study followed 120 men for a year without a comparison group; 110 completed treatment and 17% reported drug-related adverse events.855,856

15 Can sexual side effects persist after stopping?

The US label says sexual effects may persist after stopping, with dutasteride’s role in persistence unknown. The observed sexual events resolved during follow-up in a smaller hair-loss trial. Canada’s June 2026 bulletin describes plans to strengthen sexual-dysfunction warnings.840,857,858

16 Can scalp injections cause hair loss?

Published case series describe bald patches after dutasteride scalp injections, including scarring and incomplete regrowth. How often this happens is not known.843,844

17 Why do studies rank hair-loss treatments differently?

They measure different outcomes over different periods. A treatment can rank first for total hair count at 24 weeks while another leads for terminal hair count. Comparisons also differ in dose, patient selection and whether treatments were tested directly against each other.859

18 Has every trial found dutasteride better than finasteride?

No. Larger trials have favored dutasteride on particular hair measurements, but a 2026 Iranian trial in 46 men found no significant difference in hair improvement after 24 weeks. Trial size and the outcome measured affect the result.851,847

19 What evidence is there for women with hair loss?

A Korean study followed 24 women taking oral dutasteride and found higher hair density, with no increase in average hair thickness. It had no untreated comparison group. The US Avodart label has no indication for women and warns about fetal exposure.860,840

20 What can combination studies tell us?

They show what happened with the whole treatment. A seven-man hair study combined minoxidil, dutasteride and copper peptides while topical minoxidil continued. It used photographs and could not isolate which ingredient contributed.861

21 Is a generic the same as a compounded product?

They follow different approval paths. An FDA-approved generic must meet bioequivalence and other quality requirements. Compounded drugs have no FDA approval review of their safety, effectiveness or quality before marketing.862,863

22 Does a higher price mean it works better?

FDA explains that approved generics can cost less because competition and lower development costs reduce prices, while bioequivalence requirements still apply. Price alone cannot show whether a product is effective.862

23 What does FDA approval tell me about a generic?

FDA reviews generic drugs for quality, manufacturing and bioequivalence. An approved generic must have the same active ingredient, strength, dosage form and route as the reference medicine.862

24 Which schedules have actually been studied?

The 917-man trial studied daily oral dutasteride at 0.02, 0.1 and 0.5 mg for 24 weeks, alongside finasteride and placebo. A later 60-man pilot tested intermittent oral schedules. Each result belongs to its study population, formulation and comparison.851,854

25 Does lowering DHT also lower testosterone?

Dutasteride blocks conversion of testosterone to DHT. In the US-label BPH studies, DHT fell while median testosterone rose, remaining within the physiological range. The two hormone measurements describe different effects.840

26 What does the label say about storage?

The US Avodart label specifies 25°C, with permitted excursions from 15°C to 30°C. It also warns about skin exposure to the capsule contents during pregnancy. Those instructions describe the labeled capsule product.840

27 How long does it stay in the body after stopping?

The US label gives a steady-state half-life of about five weeks. Dutasteride can remain detectable for four to six months after the last dose. The label uses that persistence in its blood-donation precautions.840

28 Why does the label say to swallow capsules whole?

The contents can irritate the mouth and throat. The label says capsules should be swallowed whole rather than chewed or opened. The intact capsule is the formulation covered by those instructions.840

29 Is weight gain a known side effect?

Weight gain is not listed among the common adverse reactions in the US Avodart label. Those tables chiefly describe older men with BPH. They provide limited information about weight changes in younger people treated for hair loss.840

30 Has it been studied for children?

The US Avodart label says pediatric safety and effectiveness have not been established. It has no pediatric indication.840

31 Can other medicines change dutasteride exposure?

Yes. Dutasteride is metabolized by CYP3A4 and CYP3A5 enzymes. The US label calls for caution with long-term use of potent CYP3A4 inhibitors because exposure may increase.840

sources for this chapter

  1. Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Checked October 1, 2026. Selected primary-source passages reviewed.
  2. Avodart US prescribing information Checked October 1, 2026. Selected primary-source passages reviewed.
  3. Zagallo capsules 0.1 mg / 0.5 mg (translated) Checked October 1, 2026. Selected primary-source passages reviewed.
  4. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. Checked October 1, 2026. Selected full-text passages reviewed.
  5. Paradoxical Nonscarring Alopecia Following Mesotherapy with Dutasteride: A Case Series. Checked October 1, 2026. Abstract and record reviewed.
  6. Persistent Alopecic Patches Following Dutasteride Mesotherapy for Female Androgenetic Alopecia: A Case Series. Checked October 1, 2026. Abstract and record reviewed.
  7. Preliminary short- and medium-term effects in large-volume benign prostatic hyperplasia (translated) Checked October 1, 2026. Abstract and record reviewed.
  8. Intravesical prostatic protrusion and response to dutasteride in benign prostatic hyperplasia (translated) Checked October 1, 2026. Abstract and record reviewed.
  9. Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran. Checked October 1, 2026. Abstract and record reviewed.
  10. Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters. Checked October 1, 2026. Selected full-text passages reviewed.
  11. Finasteride- and dutasteride-containing medicinal products - referral Checked October 1, 2026. Selected primary-source passages reviewed.
  12. Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction Checked October 1, 2026. Selected primary-source passages reviewed.
  13. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Checked October 1, 2026. Abstract and record reviewed.
  14. Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial. Checked October 1, 2026. Selected full-text passages reviewed.
  15. New safety information for Finasteride-Teva and Dutasteride-Teva (translated) Checked October 1, 2026. Selected primary-source passages reviewed.
  16. Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, parallel-group pilot study. Checked October 1, 2026. Abstract and record reviewed.
  17. Dutasteride improves male pattern hair loss in a randomized study in identical twins. Checked October 1, 2026. Selected full-text passages reviewed.
  18. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. Checked October 1, 2026. Abstract and record reviewed.
  19. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. Checked October 1, 2026. Abstract and record reviewed.
  20. Health Product InfoWatch: June 2026 Checked October 1, 2026. Selected primary-source passages reviewed.
  21. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. Checked October 1, 2026. Abstract and record reviewed.
  22. Study of the clinical treatment effects and mechanism of dutasteride in female-pattern hair loss (translated) Checked October 1, 2026. Abstract and record reviewed.
  23. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. Checked October 1, 2026. Selected primary-source passages reviewed.
  24. Generic Drug Facts Checked October 1, 2026. Selected primary-source passages reviewed.
  25. Understanding the Risks of Compounded Drugs Checked October 1, 2026. Selected primary-source passages reviewed.

research reference, not medical advice. The Reptides Guide: Edition 1, October 2026 / Working draft.